Tuesday, November 12, 2019
8:00AM – 4:00PM
The Willard
1401 Pennsylvania Ave NW
Thank you to all that attended! We look forward to seeing everyone next year. Panel whitepapers and slides are available below.
Panel 1 Whitepaper – Panel 1 Slides
Panel 2 Whitepaper – Panel 2 Slides
Panel 3 Whitepaper – Panel 3 Slides
Click here to read the full recap!
Friends of Cancer Research (Friends) is proud to host our Annual Meeting to address critical issues in the development of new oncology drugs and diagnostics. This meeting brings together leaders in cancer drug development, federal health and regulatory agencies, academic research, the private sector, and patient advocates for focused discussions on key issues surrounding the development and regulation of cancer drugs and therapies.
This year’s meeting features panels and experts that will propose unique approaches toward the following vital topics in drug development:
- Characterizing the Use of External Comparators for Augmenting Randomized Control Arms and Confirming Benefit
- Data Generation (and Review Considerations) for Use of a Companion Diagnostic for a Group of Oncology Therapeutic Products
- Immuno-Oncology Combination Drug Development for Patients with Relapsed/Refractory Disease After Initial PD-(L)1 Therapy
Final Agenda
8:00 AM – Registration and Breakfast
8:30 AM – Welcome
- Ellen Sigal, Chairperson & Founder, Friends of Cancer Research
- Jeff Allen, President & CEO, Friends of Cancer Research
8:45 AM – Panel 1: Characterizing the Use of External Controls for Augmenting Randomized Control Arms and Confirming Benefit
- Moderator: Gary Rosner, Johns Hopkins University
- Bill Capra, Genentech
- Ruthie Davi, Acorn AI, a Medidata Company
- Bindu Kanapuru, FDA
- Erik Pulkstenis, AbbVie
- Jeremy Rassen, Aetion
- Dirk Reitsma, PPD
- Meghna Samant, Flatiron Health
10:30 AM – Break
10:45 AM – Panel 2: Immuno-Oncology Drug Development for Patients with Disease Progression After Initial anti-PD-(L)1 Therapy
- Moderator: Ryan Sullivan, Massachusetts General Hospital
- Eric Rubin, Merck
- T.J. Sharpe, Patient Advocate
- Marc Theoret, FDA
- Maurizio Voi, Novartis
12:30 PM – Lunch
1:00 PM – Lunch Keynote Conversation: Project Orbis
- Moderator: Richard Pazdur, FDA
- Shaily Arora, FDA
- Sanjeeve Bala, FDA
- Jaigi Mathai, Health Canada
- Susan Mayer, Eisai
- Kelly Robinson, Health Canada
- Bradley Scott, Health Canada
- Sunita Zalani, Merck
2:00 PM – Break
2:15 PM – Panel 3: Data Generation (and Review Considerations) for Use of a Companion Diagnostic for a Group of Oncology Therapeutic Products
- Moderator: Steffan Ho, Pfizer
- Andrea Ferris, LUNGevity
- David Hyman, Memorial Sloan Kettering Cancer Center
- Lynne McBride, Thermo Fisher Scientific
- Preeti Narayan, FDA
- Reena Philip, FDA
- Lakshman Ramamurthy, GlaxoSmithKline
4:00 PM – Closing Remarks
- Jeff Allen, Friends of Cancer Research
For more information or to RSVP, click the link above or contact Heather Chaney at hchaney@focr.org or (202) 944-6719. Check back soon for the final agenda.
